FDA Increasingly Concerned Over Health Claims of CBD Products

The FDA held its first public hearing May 31 to evaluate the safety and efficacy of CBD products, which have exploded onto the market claiming everything from pain relief to depression support. The FDA planned to delve into manufacturing, product quality and concentration, marketing and effects of long-term use to determine how to regulate CBD. Researchers, doctors, patients and witnesses from the supplement industry were set to testify about their experience. Dr. Ned Sharpless, acting commissioner of the FDA, pointed to the issue of safety during the hearing, as the use of CBD in food and dietary supplements is yet to be determined.